Andy Gould

VGIT offers lower volatility and lower fees, while IGIB delivers higher yields and has stronger recent returns. Which fits your portfolio?

PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings.

RWR delivered higher returns over the past one- and five-year periods, while HAUZ offers lower fees and broader diversification.

IYF has delivered stronger 5-year returns despite higher fees, while FNCL offers broader diversification.

SCHD offers lower costs and boasts stronger one-year returns than HDV, which maintains a more concentrated portfolio of high-yielding U.S. stocks.

The iShares Russell 2000 Value ETF (IWN) outperformed over the past year, but the Vanguard Morningstar Small-Cap Value ETF (VBR) -- with its lower fees -- delivered stronger five-year returns.

Small-cap growth fund ISCG delivered stronger returns over the last 12 months, while mega-cap fund MGK had the higher return over the last five years.

VFH holds a significantly greater number of companies and pays a higher dividend yield than XLF, yet both funds have delivered similar five-year returns.

VNQ delivered stronger recent returns, while VNQI offers a higher dividend yield and broader geographic diversification across 30-plus countries.

XLF delivers a higher dividend yield with lower volatility, while FTEC has posted a higher return over the past year.

MGK delivered higher five-year returns along with a steeper maximum drawdown than VONG over the same period.

RWR delivered higher returns over the last year with lower fees, while GQRE offers broader international exposure and a higher dividend yield.

NZAC includes emerging markets and applies strict climate screens, while URTH focuses on developed-market stocks.

VFH's diversified portfolio delivered stronger five-year returns with a much lower maximum drawdown, while IAT's concentrated bet on regional banks offers a higher yield for income seekers.

IBBQ posted the stronger return over the past year, but has also experienced much higher historical volatility than XLV.

IHE's pharma-focused portfolio delivered higher returns over the past year, while XLV offers a broader healthcare focus with a much lower expense ratio.

PBE delivered the better return over the past year, but has experienced greater historical volatility. VHT's more diversified portfolio and rock-bottom fees offer investors a steadier, lower-cost option.

RWR offers broader diversification, while XLRE's more concentrated portfolio charges lower fees.

KBE targets banks exclusively with higher recent returns, while VFH offers broader financial sector exposure at a fraction of the cost.

VFH's diversified portfolio has delivered better returns over the last five years than KRE, with about half the maximum drawdown -- although KRE has had the stronger run recently.